2016;57(4):587-596.[DOI] 60
A Type 2 diabetic patient on insulin has a higher risk profile than one managed by diet or oral agents alone
The patent dance provisions of the BPCIA, which govern information exchange between the reference product sponsor and a biosimilar applicant after the 351(k) application is filed, create additional procedural timelines that typically add 18 to 36 months to the effective market entry date for biosimilars even after the 12-year exclusivity expires
By addressing common questions, we aim to provide clear, useful information for current and prospective semaglutide users
Studies on bovine neutrophils suggest that increasing choline concentrations linearly diminish their phagocytic and killing capacities (82)
Insulin icodec is currently marketed as Awiqli in the EU, Canada, Australia, Japan, and Switzerland to treat both type 1 and type 2 diabetes and in China to treat type 2 diabetes